title: [SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!].
authors.forename: M
authors.initials: M
authors.lastname: Nauck
authors.forename: S
authors.initials: S
authors.lastname: Del Prato
mesh_terms: D001559:Benzhydryl Compounds; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000652:urine; D005913:Glipizide / Q000009:adverse effects / Q000627:therapeutic use; D005960:Glucosides / Q000009:adverse effects / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006029:Glycosuria / Q000139:chemically induced / Q000652:urine; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects / Q000627:therapeutic use; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D001559:Benzhydryl Compounds; D005913:Glipizide; D005960:Glucosides; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D008687:Metformin; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013453:Sulfonylurea Compounds; C089180:SLC5A2 protein, human; C517652:hemoglobin A1c protein, human; C529054:dapagliflozin; C057619:glimepiride